Old Web
English
Sign In
Acemap
>
Paper
>
PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY
2019
N. Despiégel
L. Cirillo
I. Gaikwad
Keywords:
Biosimilar
Bevacizumab
Medicine
Intensive care medicine
budget impact
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]